About: Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.21 (-8.30%)
OVID NASDAQ Ovid Therapeutics Inc
Ovid Therapeutics Inc share price
OVID price activity
Last Price
$2.190
Change (24hr)
-0.23 USD (-9.34%)
Volume
519K
Volume (4w avg)
-
Open
$2.42
Day Range
$2.19 - $2.42
Previous Close
$2.41
Last Trade
13 Oct, 6:03 pm GMT+0
Delayed
13 Oct, 6:03 pm GMT+0
OVID price performance
Delayed
13 Oct, 6:03 pm GMT+0
OVID Market Signals